Actively Recruiting
Sequential MonotherApy of TicagrElor and Clopidogrel After Coronary Intervention
Led by Second Affiliated Hospital, School of Medicine, Zhejiang University · Updated on 2024-08-07
2690
Participants Needed
1
Research Sites
196 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The MATE study is a randomized, multicenter, open-label, investigator-initiated clinical trial aimed to evaluate efficacy and safety of sequential monotherapy of ticagrelor and clopidogrel in patients with acute coronary syndrome (ACS) after coronary intervention. Standard DAPT of aspirin plus ticagrelor will be given for the first 1 month after PCI. After 1 month, event-free subjects will be randomized at 1:1 ratio into receiving standard DAPT (DAPT) until 12months , or switch to ticagrelor monotherapy for another 5 months , and further de-escalated to monotherapy of clopidogrel for the last 6 months(SAPT).
CONDITIONS
Official Title
Sequential MonotherApy of TicagrElor and Clopidogrel After Coronary Intervention
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18-80 years old
- Diagnosed with acute coronary syndrome upon admission
- Received ticagrelor for at least 30 days after successful PCI with current-generation drug-eluting stents
- Agree to follow the study protocol and clinical follow-up schedule and provide written informed consent
You will not qualify if you...
- Implanted with first-generation drug-eluting stents or bioabsorbable stents during hospitalization
- Active pathological bleeding such as peptic ulcer or intracranial hemorrhage
- History of intracranial hemorrhage, intracranial neoplasms, intracranial vascular malformations, or hemangioma
- High risk of major bleeding including acute or chronic gastrointestinal ulcers, malignant tumors, etc.
- Received thrombolytic therapy within 24 hours of the index PCI
- Planned coronary revascularization within 30 days
- Allergic to ticagrelor, clopidogrel, aspirin, or excipients
- Unable to tolerate 12-month dual antiplatelet therapy for any reason
- Cardiogenic shock or hemodynamic instability
- Diagnosed with active hepatitis or liver cirrhosis upon admission
- Known serious progressive disease with estimated survival less than 12 months
- Platelet count below 100,000/mm3
- Dialysis-dependent renal failure
- Requires oral anticoagulation therapy
- Pregnant or planning pregnancy within 1 year
- Conditions interfering with study procedures such as dementia, immobility, or alcohol use
- Participating in other clinical trials with investigational drugs or devices not meeting primary endpoints
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
2nd Affiliated Hospital, School of Medicine at Zhejiang University
Hangzhou, Zhejiang, China, 310009
Actively Recruiting
Research Team
H
Heyang Wang, MD
CONTACT
C
Changling Li, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here